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Abstract
Aims/hypothesis Insulin degludec (Des(B30)LysB29(γ-Glu
Nε-hexadecandioyl) human insulin; IDeg) is a new basal
insulin with an ultra-long flat action profile. The acute
physiological responses to hypoglycaemia with IDeg and
insulin glargine (A21Gly,B31Arg,B32Arg human insulin;
IGlar) were compared.
Methods Twenty-eight adult type 1 diabetic patients with
normal hypoglycaemia awareness (age=41±12 years,
HbA1c=7.8±0.6% [62.8±7 mmol/mol]) were randomised to
once-daily IDeg or IGlar for 5 days in a two-period crossover
design. Participants and research staff were blinded to group
assignment. Patients were assigned the lowest available
randomisation number from a set of blinded randomisation
codes provided by the trial sponsor. Hypoglycaemia was
induced by administering three times the usual daily insulin
dose at midnight on day 5. Plasma glucose (PG) was stabilised
by glucose clamp (5.5 mmol/l) for 7–9 h post dosing. Next
morning, PG was allowed to decrease stepwise from 5.5 to
3.5 mmol/l (maintained for 30 min) to 2.5 mmol/l (for
15 min). PG was then increased to 3.9 mmol/l (for 120 min),
before being returned to baseline. Hypoglycaemic symptom
score (HSS), hypoglycaemic awareness, cognitive function,
counter-regulatory hormones and vital signs were assessed
during each glucose plateau. The primary analysis was to
compare IDeg vs IGlar with respect to HSS at nadir PG
concentration (2.5 mmol/l).
Results The full analysis set for treatment comparisons com-
prised data from all 28 exposed patients. Rates of PG decline
and PG at nadir were similar for IDeg and IGlar. No treatment
differences in HSS (estimated difference: 0.17 [95% CI −1.71,
2.05]; p >0.05), cognitive function or awareness were ob-
served at any time. Growth hormone and cortisol responses
during hypoglycaemia were greater with IDeg than IGlar
(AUC treatment ratio [IDeg/IGlar]: 2.44 [1.30, 4.60], p <0.01;
and 1.23 [1.01, 1.50]; p <0.05), and adrenaline (epinephrine)
responses trended higher (1.40 [0.96, 2.04], p =0.07). The rates
of recovery from hypoglycaemia were similar.
Conclusions/interpretation IDeg and IGlar elicit compara-
ble symptomatic and cognitive responses to induced
hypoglycaemia. IDeg may elicit a moderately greater endo-
crine response, but times to PG recovery were similar for
the two insulins.
Trial registration ClinicalTrials.gov NCT01002768.
Funding Novo Nordisk.
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Introduction
Insulin analogues are being developed to overcome the limi-
tations of current insulin therapy by producing pharmacokinet-
ic and pharmacodynamic profiles that more closely resemble
physiological insulin release. The use of long-acting insulin
analogues has been shown to reduce rates of hypoglycaemia,
particularly at night and in individuals aiming for tight
glycaemic control to minimise the risk of long-term complica-
tions. Despite this improvement, the annual prevalence of
hypoglycaemia still remains between 30% and 40% in patients
with type 1 diabetes. Nearly 50% of well-controlled individ-
uals with longstanding type 1 diabetes experience at least one
severe hypoglycaemic episode over 9–12 months [1]. Severe
episodes of hypoglycaemia are less frequent in patients with
diabetes who still have hypoglycaemia awareness [2], but these
patients are still at significant risk of hypoglycaemia due to
lack of adequate glucagon secretion and a reduced response of
other counter-regulatory hormones [1]. Furthermore, with a
longer duration of type 1 diabetes the risk for hypoglycaemia
increases and hypoglycaemia awareness becomes reduced [3].
Although the risk of severe hypoglycaemia is partly related
to impaired release of counter-regulatory hormones, the main
clinical cause is inappropriately high insulin levels at vulnera-
ble time points. Insulin degludec (Des(B30)LysB29(γ-Glu
Nε-hexadecandioyl) human insulin; IDeg) is a new ultra-
long-acting basal insulin analogue with an extended duration
of action beyond 42 h [4], a flat insulin profile with once-daily
dosing [5] and lower intrapatient variability [6]. Using IDeg,
insulin-naive and insulin-treated patients with type 2 diabetes
showed a significantly reduced risk of overall and nocturnal
hypoglycaemia events [7]; in patients with type 1 diabetes, a
similar result regarding nocturnal hypoglycaemia was found
[8, 9]. New insulin analogues with a very long action profile
carry the potential risk of prolonged hypoglycaemia. This is
particularly important in type 1 diabetes where the risk of
hypoglycaemia is increased even further by poor hormonal
counter-regulation and deteriorating hypoglycaemia aware-
ness. Insulin analogues for type 1 diabetes therapy should thus
be tested to ensure they are not associated with a further
impairment of the remaining counter-regulation. To investigate
the symptomatic, cognitive and counter-regulatory hormone
response to hypoglycaemia induced by IDeg compared with
that of an existing, clinically well-established, long-acting
basal insulin, insulin glargine (A21Gly,B31Arg,B32Arg hu-
man insulin; IGlar), we performed a double-blind randomised
crossover study in patients with type 1 diabetes.
Methods
Setting and participants We enrolled patients with type 1
diabetes between 18 and 65 years of age who were
considered to still have hypoglycaemia awareness and were
not suffering from any other comorbidities. Patients had a
BMI between 18.0 and 28.0 kg/m2, an HbA1c between
6.7% (50 mmol/mol) and 10.0% (86 mmol/mol) and a total
daily insulin dose below 1.2 U/kg (basal insulin ≥0.2 U/kg).
Key exclusion criteria were: prior IGlar therapy (within
3 months of screening); recurrent severe hypoglycaemia
(more than one severe hypoglycaemic event during the last
12 months); hypoglycaemia unawareness (as judged by the
medical investigator); pregnancy; impaired renal or hepatic
function; impaired vision; and cardiac disease. All partici-
pants gave signed informed consent before participating in
any trial activities. The trial was performed after approval
by the local ethics committee and according to good clin-
ical practice [10] and the Declaration of Helsinki [11].
Trial design This double-blind randomised crossover trial
was designed to compare the development of symptomatic,
cognitive and counter-regulatory hormone response to acute
hypoglycaemia induced by IDeg or IGlar in adults with
type 1 diabetes. Patients were randomly allocated to
double-blind treatment with subcutaneous injections of ei-
ther IDeg (Tresiba, 100 U/ml 3 ml Penfill cartridges [Novo
Nordisk, Bagsværd, Denmark]) or IGlar (Lantus, 100 U/ml,
3 ml cartridges [Sanofi, Paris, France]) once daily for a run-
in period of 5 days over two separate treatment periods,
with a wash-out period of 13–21 days between periods
(during which usual insulin therapy was resumed). Patients
were assigned the lowest available randomisation number
from a set of blinded randomisation codes provided by the
sponsor (Novo Nordisk).
A run-in period of 5 days was based on model calcula-
tions indicating that stable steady-state levels for both in-
sulins were achieved within 2–3 days of once-daily dosing.
Two days were added during which patients were at steady
state, resulting in a total run-in period of 5 days. During the
5 day run-in period, each patient was asked to provide at
least four plasma glucose (PG) measurements per day and
to record any hypoglycaemic events. Patients were required
to attend the clinic on each day for administration of the
trial insulin. All injections were performed by a person not
otherwise involved with the study to keep the double-blind
character of the trial. Sequence allocation was carried out
according to a computer-generated randomisation list. Dur-
ing the treatment periods, insulin aspart (B28Asp human
insulin) (NovoRapid, 100 U/ml [Novo Nordisk]; available
as a 3 ml FlexPen) was administered as bolus insulin.
During the first 4 days of each treatment period, the basal
insulin dose was set to 80% of the patients’ total daily basal
insulin dose to minimise the risk of hypoglycaemia, and
dose levels remained the same during both treatment pe-
riods. Insulin was administered s.c. in the thigh at approx-
imately 20:00 hours on days 1–4 in each treatment period.
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On day 5 the stepwise hypoglycaemic glucose clamp pro-
cedure was started. Patients were admitted to the clinic
before 20:00 hours for an in-house stay of at least 50 h.
At the discretion of the investigator, patients stayed at the
clinic to ensure stabilisation of blood glucose values after
completion of glucose clamp procedures.
Stepwise hypoglycaemic glucose clamp procedure We were
able to initiate the hypoglycaemic glucose clamp procedure as
planned in all patients as no patients had experienced any
hypoglycaemic episodes (PG ≤3.9 mmol/l) during the previous
24 h. To achieve a PG target of 5.5 mmol/l (±30%) for the run-
in period of 7–9 h, patients received a variable intravenous
glucose infusion (10%; Braun Infusomat FM; Melsungen,
Germany) or human soluble insulin infusion (40 U Actrapid
[100 U/ml] in 99.6 ml NaCl [154 mmol/l]) which was initiated
at approximately 22:00 hours. To facilitate hypoglycaemia
induction, a three-times-higher basal insulin dose was admin-
istered at midnight (range of timing ±3 min), replacing the
regular basal insulin dose given at 20:00 hours (Fig. 1). After
the midnight dosing, insulin infusion was stopped when
glucose levels had dropped by approximately 0.3 mmol/l
(5 mg/dl). At 30 min prior to hypoglycaemia induction (in
the morning), PG was maintained at 5.5 mmol/l but with a
deviation of only ±10%. Patients remained fasting in a supine
or semi-supine position throughout the hypoglycaemic glucose
clamp procedure, except when cognitive function tests were
performed. Glucose infusion was stopped to induce
hypoglycaemia. PG was allowed to decrease to target levels
of 3.5 and 2.5 mmol/l (nadir) in a stepwise fashion. Variable
glucose infusion was resumed at each step to maintain PG at
the target level for fixed periods of 30 and 15 min, respectively.
Controlled recovery from hypoglycaemia was initiated after
the nadir period. Glucose was infused at a fixed rate of
5.5 mg kg−1 min−1 until PG reached the recovery target of
3.9 mmol/l. PG was clamped at 3.9 mmol/l by variable i.v.
glucose infusion for 120 min, before being increased to
5.5 mmol/l, where it was clamped again until it was deemed
safe to terminate the clamp procedure.
Arterialised whole-blood samples were drawn for PG,
counter-regulatory hormones and pharmacokinetic insulin
analysis throughout the procedure. Moreover, hypoglycaemic
symptoms, hypoglycaemic awareness, vital signs and cogni-
tive function were measured at time points corresponding to
specific PG concentrations according to Fig. 1.
Symptoms of hypoglycaemia and hypoglycaemic awareness
Symptoms of hypoglycaemia at each PG target level (Fig. 1)
were assessed using a validated questionnaire (Edinburgh
Hypoglycaemia Scale [12]). This scale classifies hypoglycaemic
symptoms into autonomic symptoms (sweating, palpitations,
shaking and hunger), neuroglycopenic symptoms (confusion,
drowsiness, odd behaviour, speech difficulty and incoordina-
tion) and non-specific symptoms (headache and nausea) [12,
13]. Each of the 11 symptoms was scored by the patient
on a seven point interval scale ranging from 1 (= not at all)
to 7 (= a great deal). The total score at each time point was
calculated as the mean score for all symptomsmultiplied by 11.
Hypoglycaemic
response
assessments
During recovery from
hypoglycaemia:
at 0, 60 and 120 min
after PG has reached
3.9 mmol/l
During hypoglycaemia induction:
at PG = 4.5, 4.0, 3.5, 3.0 mmol/l 
and nadir (2.5 mmol/l)
Run-in
00:00
 (midnight)
~06:00 ~07:00–09:00 Variable timing
60 min
30 min
15 min
120 min
Last dose (three times regular dose)
PG = 3.5 mmol/l
PG = 3.9 mmol/l
PG = 2.5 mmol/l
Hypoglycaemia induction Recovery
GIR
PG = 5.5 mmol/l
Fig. 1 Stepwise glucose clamp
procedure. Run in: participants
were clamped at a PG level of
5.5 mmol/l (100 mg/dl) 2 h before
dosing until 7–9 h after dosing.
Hypoglycaemia induction:
variable i.v. glucose was
terminated and PG was allowed to
decrease to 3.5 mmol/l (63 mg/dl),
maintained for 30 min, and
thereafter to a target nadir of
2.5 mmol/l (45 mg/dl), maintained
for 15 min. Recovery: at end of
nadir PG, a fixed i.v. glucose
infusion (5.5 mg kg−1 min−1) was
initiated, and PG was allowed to
increase to 3.9 mmol/l (70 mg/dl),
maintained for 120 min, and
thereafter to 5.5mmol/l (100mg/dl).
Thick broken line, variable
glucose infusion rate (GIR); thick
unbroken line, fixed i.v. glucose
infusion (5.5 mg kg−1 min−1)
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Hypoglycaemic awareness was assessed by asking the patient
the question ‘Do you feel a hypo?’
Cognitive function Cognitive function at each PG target
level (Fig. 1) was evaluated by using three cognitive func-
tion tests recognised as being sensitive to hypoglycaemia
[14]: trail making B [15, 16]; digit symbol substitution test
[17]; and the four-choice reaction time [18].
Counter-regulatory hormones Counter-regulatory hormone
responses to hypoglycaemia were measured at each PG
target level (Fig. 1). Plasma concentrations of adrenaline
and noradrenaline (norepinephrine) were quantified by RIA
(DRG Diagnostics, Springfield, IL, USA) and glucagon by
RIA (ICN, New York, NY, USA). Serum concentration of
growth hormone was measured using a chemiluminescent
immunoassay (CLIA) (Immolite; Siemens Healthcare Diag-
nostics, New York, NY, USA) and cortisol by CLIA (Centaur;
Siemens Healthcare Diagnostics).
Vital signs Vital signs (diastolic and systolic blood pressure
and pulse) at each PG target level (Fig. 1) were assessed
after the participant had rested for at least 5 min in a supine
position.
Statistical analysis For the primary endpoint, hypoglycaemic
symptom score (HSS) at nadir, using an SD of 13.5 [19] and a
significance level of 5%, it was calculated that 26 completers
were required to yield sufficient power (83%) to detect an
eight point difference between IDeg and IGlar. Twenty-eight
patients were enrolled to allow for dropouts.
Endpoints were compared between IDeg and IGlar using
a linear mixed model, with treatment period and treatment
as fixed effects and patients as a random effect (assuming
the random patient effect and error term were independent).
For analysis of baseline-adjusted HSS, baseline HSS was
included as a continuous covariate. For PG concentration at
nadir and counter-regulatory hormone response during de-
velopment of hypoglycaemia, estimated as AUC for the
period between PG 4.0 mmol/l and PG nadir, endpoints
were log-transformed before analysis.
Rates of increase in HSS and vital signs and deteriora-
tion in cognitive function during hypoglycaemia induction
were analysed by comparing the slopes for IDeg and IGlar,
including target PG level as a continuous covariate (4.5,
4.0, 3.5, 3.0 and 2.5 mmol/l [nadir]) in the model, an
interaction between treatment and target PG level, and
adjusted for baseline value. The same approach was used
for rate of increase in counter-regulatory hormone response
(though log-transformed and not baseline adjusted). The
assumption of a common intercept for IDeg and IGlar at
PG level 5.5 mmol/l was tested with a significance level of
5% for each endpoint.
PG decline with IDeg and IGlar was compared by calcu-
lating the time from the start of hypoglycaemic induction
(5.5 mmol/l) until each PG target level (4.5, 4.0, 3.5,
3.0 mmol/l and nadir). Rate of PG decline was evaluated from
target PG=4.5 mmol/l to nadir to demonstrate that the profiles
were comparable during development of hypoglycaemia. Dif-
ferences in time were log-transformed and analysed using the
same general model as described above, though with target
PG level as a continuous covariate and an interaction between
treatment and target PG levels (assuming the possibility of
different treatment slopes and a common intercept for IDeg
and IGlar at PG=5.5 mmol/l).
During recovery from hypoglycaemia, the slopes for IDeg
and IGlar were compared for each variable using the same
models as described for development of hypoglycaemia,
substituting target PG level with time (as a continuous
covariate) at 0, 60 and 120 min.
The amount of glucose required to stabilise individual glu-
cose levels at baseline (5.5 mmol/l), during development of
hypoglycaemia (3.5 and 2.5 mmol/l [nadir]) and during the
entire recovery period (from end of nadir PG to end of the 2 h
period at 3.9mmol/l) was estimated asAUCof glucose infusion
rate, log-transformed and analysed using the general model.
Results
Participant characteristics and trial flow A total of 28
eligible men and women with type 1 diabetes were enrolled
in the trial (Fig. 2). Baseline demographic characteristics
are summarised in Table 1. Two patients were withdrawn
Screened
(n=36)
Randomised
(n=28)
Completed 1st
treatment 
period
Completed 2nd 
treatment 
period
Completed (n=26) 
Analysed FAS (n=28)
Withdrawn, adverse event
(n=2)
Withdrawal of consent (n=1)
HbA1c >10.0% (n=4) 
Abnormal ECG (n=2)
Excluded (n=8)
Smoker (n=1) 
Fig. 2 Flow of participants through the trial. FAS, full analysis set
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after the first treatment period because of the onset of
adverse events. The full analysis set for treatment compar-
isons comprises data from all 28 exposed patients.
Glycaemic state prior to the hypoglycaemic clamp experiments
On each of the 5 days prior to the hypoglycaemic clamp
experiment, glycaemic control was similar for IDeg and IGlar,
measured by four-point self-measured PG profiles. For both
insulins, low and similar numbers of hypoglycaemic
episodes were reported on each of the 5 days prior to
the hypoglycaemic clamp experiment (data not shown).
The trial protocol required that no hypoglycaemia oc-
curred for any patient in the 24 h immediately before
the start of the clamp experiment.
Plasma glucose and glucose infusion rate As required by
the study design, hypoglycaemia induction could only com-
mence once PG had been at 5.5 mmol/l±10% for 30 min.
During this period, geometric mean PG levels (CV%) were
5.5 mmol/l (3.8%) and 5.5 mmol/l (4.9%) for IDeg and
IGlar, respectively. Hypoglycaemia induction could occur
between 07:00 and 09:00 hours in the morning of day 5;
mean actual time of hypoglycaemia induction was
07:26 hours for IDeg and 07:32 hours for IGlar.
Mean PG profiles were similar with IDeg and IGlar
throughout the hypoglycaemic clamp procedure (Fig. 3a).
The rate of PG decline from baseline (5.5 mmol/l) to
4.5 mmol/l was slightly lower with IDeg than IGlar, but rates
were identical for both insulins at PG below 4.5 mmol/l. There
was no significant difference in nadir PG levels between
treatments (estimated geometric mean [CV%] 2.6 [9.4] vs
2.5 [9.7] mmol/l; estimated treatment ratio [IDeg/IGlar]:
1.03 [95% CI 0.99, 1.08], p =0.12). Similarly, time to PG
recovery from nadir to 3.9 mmol/l (when glucose was infused
i.v. at a fixed rate of 5.5 mg kg−1 min−1; see Fig. 1) was not
significantly different for the two treatments: estimated geo-
metric mean 8.1 vs 10.9 min; and estimated treatment ratio
0.75 (95% CI 0.56, 1.02), p =0.07.
Variable glucose infusion rates during the clamp procedure
tended to be lower with IDeg than IGlar (Fig. 3b). Significant
treatment differences in the rate of glucose infusion were
observed both at baseline (PG target =5.5 mmol/l) (estimated
treatment ratio [IDeg/IGlar]: 0.55 [95% CI 0.41, 0.74], p<0.01)
and during the post nadir 2 h clamp (3.9 mmol/l) (estimated
treatment ratio: 0.71 [95% CI 0.53, 0.93], p =0.02).
HSS Mean HSS increased similarly for IDeg and IGlar
during hypoglycaemia induction (Fig. 4). HSS increased for
both insulins when PG level dropped below 4.0 mmol/l. There
was no significant difference in baseline-adjusted HSS at nadir
(the primary endpoint) between IDeg and IGlar (5.00 vs 4.83,
estimated treatment difference 0.17 [95% CI −1.71, 2.05]).
During recovery from hypoglycaemia, mean HSS returned to
baseline at a similar rate for IDeg and IGlar (Fig. 4).
Cognitive function scores Overall deterioration and resto-
ration of cognitive function during development of and re-
covery from hypoglycaemia was similar with IDeg and IGlar
(Fig. 5). Measurable treatment differences were detected only
during the development of hypoglycaemia, where the number
of correct responses given to the digit symbol substitution test
(DSST; Fig. 5b) declined at a significantly greater rate with
IGlar than with IDeg, and the treatment difference in DSST at
Table 1 Demographic and baseline characteristics (n =28)
Characteristic Mean ± SD Range
Sex (female/male) 8/20
Age (years) 40.7±11.7 22.0–65.0
BMI (kg/m2) 25.1±2.7 19.1–27.9
Duration of diabetes (years) 20.6±9.9 4.5–50.5
HbA1c (%) 7.8±0.6 6.9–9.3
HbA1c (mmol/mol) 62.8±7 52–78
Fasting PG (mmol/l) 9.5±3.4 3.7–16.9
Basal insulin (U kg−1 day−1) 0.32±0.1 0.20–0.59
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PG nadir was significant (estimated treatment difference in
slope (IDeg–IGlar) 5.93 [95% CI 1.23, 10.62], p <0.05).
Hypoglycaemic awareness Hypoglycaemic awareness was
similar at all PG levels for IDeg and IGlar, occurring in 8%
and 4% of patients, respectively, at 5.5 mmol/l, increas-
ing to a maximum of 74% and 68% of patients at PG
nadir (not tested).
Counter-regulatory hormones Counter-regulatory hormone
responses during development of hypoglycaemia were
moderately greater with IDeg than with IGlar for three of
the five hormones monitored (Fig. 6). No differences in
hormone levels were detected between treatments at base-
line (5.5 mmol/l, p >0.05). Growth hormone, cortisol and
adrenaline levels increased more rapidly during develop-
ment of hypoglycaemia after treatment with IDeg than with
IGlar (estimated treatment ratio in slope [IDeg/IGlar] 1.35
[95% CI 1.19, 1.54], 1.03 [95% CI 1.00, 1.06] and 1.07
[95% CI 1.01, 1.14], respectively). Overall growth hor-
mone and cortisol responses during development of
hypoglycaemia were significantly greater with IDeg than
with IGlar (growth hormone AUC [ng min ml−1] estimated
geometric mean 498 vs 204, estimated treatment ratio 2.44
[95% CI 1.30, 4.60], p <0.01; and cortisol AUC [nmol min
l−1] 29,891 vs 24,301, treatment ratio 1.23 [95% CI 1.01,
1.50], p <0.05). These differences were also significant at
nadir PG, with IDeg being greater than IGlar (estimated
treatment ratio 1.85 [95% CI 1.06, 3.21], p =0.031, and
1.16 [95% CI 1.00, 1.34], p =0.049 for growth hormone
and cortisol response, respectively). A similar though non-
significant trend was observed for adrenaline response dur-
ing development of hypoglycaemia (AUC [pmol min l−1]
estimated geometric mean 36,233 vs 25,804, estimated
treatment ratio 1.40 [95% CI 0.96, 2.04], p =0.07); howev-
er, no significant difference in plasma adrenaline levels
could be detected between IDeg and IGlar at nadir. Nor-
adrenaline and glucagon levels developed similarly during
acute hypoglycaemia when induced by either insulin.
Counter-regulatory hormones returned to baseline at similar
rates for IDeg and IGlar.
Vital signs Diastolic blood pressure decreased similarly
during the development of hypoglycaemia with both treat-
ments: comparing IDeg with IGlar (estimated treatment
difference in slope [IDeg–IGlar] −0.42 [95% CI −1.18,
0.35]). No effect on either systolic blood pressure or pulse
was observed with either IDeg or IGlar. At nadir PG, there
a
b
c
d
-8
-6
-4
-2
0
2
4
TM
B
 (s
)
-14
-8
-6
-4
-2
0
2
4
D
SS
T 
sc
o
re
 
(nu
mb
er 
of 
co
rre
ct 
res
po
ns
es)
-2.0
-0.5
0.0
0.5
1.0
4C
RT
 
 
(%
)
-20
-10
0
10
20
30
40
50
4C
RT
 
 
(m
s)
Nadir 0 60 1204.5 4.0 3.5 3.0
PG (mmol/l)
Hypoglycaemia induction
Time (min)
Recovery (PG = 3.9 mmol/l)
-12
-10
1.5
-1.0
-1.5
60
*
Nadir 0 60 1204.5 4.0 3.5 3.0
PG (mmol/l)
Hypoglycaemia induction
Time (min)
Recovery (PG = 3.9 mmol/l)
Nadir 0 60 1204.5 4.0 3.5 3.0
PG (mmol/l)
Hypoglycaemia induction
Time (min)
Recovery (PG = 3.9 mmol/l)
Nadir 0 60 1204.5 4.0 3.5 3.0
PG (mmol/l)
Hypoglycaemia induction 
Time (min)
Recovery (PG = 3.9 mmol/l)
Fig. 5 Baseline-adjusted cognitive function performance test scores dur-
ing development of, and recovery from, hypoglycaemia for (a) trail making
B, (b) digit symbol substitution test (DSST), (c) four-choice reaction time
(percentage correct answers) and (d) four-choice reaction time (response
time). Black circles, IDeg; white squares, IGlar; vertical bars, SEM.
*denotes statistically significant estimated treatment difference in slopes
(p <0.05). TMB, trail making B; 4CRT, four-choice reaction time
-1
0
1
2
3
4
5
H
SS
Nadir 0 60 1204.5 4.0 3.5 3.0
PG (mmol/l)
Hypoglycaemia induction
Time (min)
Recovery (PG = 3.9 mmol/l)
6
7
Fig. 4 Baseline-adjusted HSS during development of, and recovery
from, hypoglycaemia. Black circles, IDeg; white squares, IGlar; ver-
tical bars, SEM
Diabetologia (2014) 57:40–49 45
was no statistically significant difference between IDeg and
IGlar with regard to pulse or blood pressure. Vital signs
returned to baseline at similar rates for IDeg and IGlar.
Safety and tolerability One serious adverse event was re-
ported after the first dose in the IDeg treatment period. At
30 min after trial drug injection, one patient developed a
mild swelling of the face and a general erythema of the skin
(reported as an anaphylactic reaction). The patient was
subsequently withdrawn from the trial and recovered
completely without the need for medical intervention. An-
other patient withdrew after completing the IDeg treatment
period because of the onset of mild influenza. Overall, 28
adverse events were reported for 18 patients; the majority
of events were mild headache (16 events, seven with IDeg
and nine with IGlar). Two adverse events (myopia and
anaphylactic reaction) were considered to have a possible
relation to IDeg. No clinically significant changes in vital
signs, ECG or safety laboratory variables from screening to
follow-up were observed.
Discussion
This is the first study to examine how the ultra-long-acting
basal insulin IDeg (estimated duration of action >42 h) affects
the hypoglycaemic response during development of, and re-
covery from, hypoglycaemia in patients with type 1 diabetes.
The results indicate that there are no marked differences in
hypoglycaemic response or hypoglycaemic awareness induced
by IDeg compared with the long-acting basal insulin IGlar.
Similar effects on hypoglycaemic symptom and cognitive
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Fig. 6 Counter-regulatory hormone response during development of,
and recovery from, hypoglycaemia for (a ) growth hormone, (b )
cortisol, (c) adrenaline, (d ) noradrenaline and (e ) glucagon. Black
circles, IDeg; white squares, IGlar; vertical bars, SEM. *denotes
statistically significant estimated treatment difference in slopes
(p <0.05)
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function scores during hypoglycaemia induction, PG nadir and
recovery from hypoglycaemia were observed with both insu-
lins. One interesting observation was a modest effect in en-
hancing some of the counter-regulatory hormone responses
around the glucose nadir with IDeg, and a lower glucose
infusion rate during recovery with IDeg compared with
IGlar; however, this had no obvious effect on the HSS
or cognitive function.
The main strengths of this trial relative to other hypo-
glycaemic experimental designs include the extensivemeasure-
ment of symptomatic, cognitive and counter-regulatory hor-
monal responses and the double-blind crossover design, which
eliminates potential investigator and patient bias as well as
inter-patient variability. Given that IDeg has a duration of
action >42 h, we considered it important to characterise how
recovery from hypoglycaemia induced by IDeg develops with
respect to the increase in PG and the persistence of symptoms
and effects on cognitive function in advance of the introduction
of IDeg into clinical practice. Finally, we included people with
type 1 diabetes, rather than healthy patients, to ensure the
pharmacodynamic response was not confounded by endoge-
nous insulin production [20–22]. In addition, intrapatient var-
iability is likely to be lower in type 1 diabetes because of the
lack of substantial endogenous insulin production. Though we
recognise that a degree of hypoglycaemia unawareness is in-
evitable in a study population with an average diabetes duration
of 21 years and is a study limitation, our main goal was to
assess the counter-regulation in a clinically relevant type 1
diabetes population. Results, particularly from HSS, indicate
sufficient hypoglycaemia awareness in all participating pa-
tients. Patients with severe hypoglycaemia unawareness were
excluded from the study altogether.
We used a stepwise hypoglycaemic clamp technique using
s.c. delivery in an attempt to achieve highly standardised study
conditions to compare physiological and counter-regulatory
responses with IDeg and IGlar. Although experimental
hypoglycaemic studies involving other basal insulins have
generally used a model incorporating i.v. delivery [23–25],
we considered s.c. administration more appropriate. This ap-
proach is more clinically relevant, particularly as the mode of
protraction for both IDeg and IGlar is activated by s.c. admin-
istration. We attempted to standardise trial conditions by ad-
ministering IDeg and IGlar at midnight, approximately 7 h
prior to inducing hypoglycaemia. A dose three times higher
than the patient’s regular insulin dose was administered on day
5 to try to achieve an appropriately low glucose target. The
design was based on pharmacokinetic and pharmacodynamic
modelling of existing data for both insulins. Thus, we set out to
control for differing glycaemia, and to achieve comparability
despite the use of two insulins with different action profiles.
The delay in initiating hypoglycaemia (by maintaining patients
in a euglycaemic clamp) until 7–9 h after administration of trial
insulin was designed to control for differences in depth and
duration of hypoglycaemia, and to control for the fall in
glucose towards the hypoglycaemic plateau. However, vari-
able glucose infusion rates during the clamp procedure tended
to be lower with IDeg than IGlar, particularly at baseline (7–9 h
post dosing) and during the recovery phase. Therefore, we
cannot draw any firm conclusions regarding the relation be-
tween the observed differences in counter-regulatory hormone
responses and in particular the rate of glucose recovery.
While the intensity of the hypoglycaemic response is
multifactorial, important determinants are probably prior
glycaemic experience, absolute PG level and the rate of
PG decline. The comparable self-measured PG profiles and
number of hypoglycaemic episodes suggest that glucose
control was similar for IDeg and IGlar during the 5 days
leading up to the hypoglycaemic clamp experiment. More-
over, in this trial, mean PG was similar with IDeg and IGlar
throughout the hypoglycaemic clamp procedure. The rate
of decline during hypoglycaemic induction was identical
for both insulins once PG fell below 4.5 mmol/l, suggesting
that the hypoglycaemic stimulus was comparable during
clamp procedures. This is an important criterion for com-
paring the response between the two insulins.
We observed moderate differences in counter-regulatory
hormone responses (as measured by the rate of increase,
AUC and hormone level at PG nadir) during the development
of hypoglycaemia for three of the five counter-regulatory hor-
mones (adrenaline, growth hormone and cortisol) when in-
ducedwith IDeg comparedwith IGlar; however, the underlying
mechanism for the observed differences could not be identified
in this study. As glucagon responses to hypoglycaemia are
attenuated by both type 1 diabetes and hyperinsulinaemia
[21], it is not surprising that no differences in glucagon re-
sponse were observed. Elevated cortisol levels have been as-
sociated with autonomic failure [26] but more recent studies
could not confirm this finding [27, 28]. Enhanced counter-
regulatory hormone response might contribute to a reduced
risk of hypoglycaemia, an important limiting factor in achiev-
ing good glycaemic control with intensified insulin therapy.
Although basal insulins such as IGlar are associated with a
reduction in severe and nocturnal hypoglycaemia compared
with neutral protamine Hagedorn insulin [29, 30], this appears
to be due to improvements in insulin kinetics rather than to
differences in glucose counter-regulation. Comparable physio-
logical responses to induced hypoglycaemia have been shown
for IGlar and human insulin in a stepped hypoglycaemic clamp
[24] and clinical trials have shown comparable glycaemic
control with IDeg and IGlar when treated to target [31, 32].
Moreover, results from the large-scale confirmatory clin-
ical trials provide promising evidence of a lower risk of
hypoglycaemia with IDeg compared with IGlar, particularly at
night [7–9].
In conclusion, this trial provides reassuring data regard-
ing the response to hypoglycaemia association with IDeg.
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IDeg and IGlar elicit comparable symptomatic and cognitive
responses to induced hypoglycaemia, and recovery from
hypoglycaemia remains similar. Furthermore, our trial suggests
that IDeg may elicit a more pronounced endocrine response to
hypoglycaemia than IGlar, albeit modest. Whether this trans-
lates into a clinically relevant difference cannot be answered by
our trial. Adequately powered randomised multicentre studies
in clinical settings are needed to establish the relevance of the
effects of this new insulin on hypoglycaemia awareness, glu-
cose counter-regulation and particularly rates of severe
hypoglycaemia among individuals with type 1 diabetes.
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